169 related articles for article (PubMed ID: 8431895)
1. Cell growth regulation in epithelial ovarian cancer.
Bast RC; Boyer CM; Jacobs I; Xu FJ; Wu S; Wiener J; Kohler M; Berchuck A
Cancer; 1993 Feb; 71(4 Suppl):1597-601. PubMed ID: 8431895
[TBL] [Abstract][Full Text] [Related]
2. The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin.
Xu FJ; Boyer CM; Bae DS; Wu S; Greenwald M; O'Briant K; Yu YH; Mills GB; Bast RC
Int J Cancer; 1994 Oct; 59(2):242-7. PubMed ID: 7927925
[TBL] [Abstract][Full Text] [Related]
3. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian cancer.
Goff BA; Shy K; Greer BE; Muntz HG; Skelly M; Gown AM
Eur J Gynaecol Oncol; 1996; 17(6):487-92. PubMed ID: 8971524
[TBL] [Abstract][Full Text] [Related]
4. Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines.
Tyson FL; Boyer CM; Kaufman R; O'Briant K; Cram G; Crews JR; Soper JT; Daly L; Fowler WC; Haskill JS
Am J Obstet Gynecol; 1991 Sep; 165(3):640-6. PubMed ID: 1679963
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of ovarian cancers.
Berchuck A; Elbendary A; Havrilesky L; Rodriguez GC; Bast RC
J Soc Gynecol Investig; 1994; 1(3):181-90. PubMed ID: 9419769
[TBL] [Abstract][Full Text] [Related]
6. Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues.
Bast RC; Pusztai L; Kerns BJ; MacDonald JA; Jordan P; Daly L; Boyer CM; Mendelsohn J; Berchuck A
Hybridoma; 1998 Aug; 17(4):313-21. PubMed ID: 9790065
[TBL] [Abstract][Full Text] [Related]
7. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.
Xu F; Lupu R; Rodriguez GC; Whitaker RS; Boente MP; Berchuck A; Yu Y; DeSombre KA; Boyer CM; Bast RC
Int J Cancer; 1993 Feb; 53(3):401-8. PubMed ID: 7679090
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa B: implications for malignant ascites formation and tumor lymphangiogenesis.
Hsieh CY; Chen CA; Chou CH; Lai KP; Jeng YM; Kuo ML; Wei LH
J Biomed Sci; 2004; 11(2):249-59. PubMed ID: 14966375
[TBL] [Abstract][Full Text] [Related]
9. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
[TBL] [Abstract][Full Text] [Related]
10. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.
Stern DF; Heffernan PA; Weinberg RA
Mol Cell Biol; 1986 May; 6(5):1729-40. PubMed ID: 2878363
[TBL] [Abstract][Full Text] [Related]
11. Growth regulation and transformation of ovarian epithelium.
Berchuck A; Kohler MF; Boente MP; Rodriguez GC; Whitaker RS; Bast RC
Cancer; 1993 Jan; 71(2 Suppl):545-51. PubMed ID: 8420675
[TBL] [Abstract][Full Text] [Related]
12. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor.
Meden H; Kuhn W
Eur J Obstet Gynecol Reprod Biol; 1997 Feb; 71(2):173-9. PubMed ID: 9138962
[TBL] [Abstract][Full Text] [Related]
14. The N-terminal 178-amino-acid domain only of the SV40 large T antigen acts as a transforming suppressor of the HER-2/neu oncogene.
Kao MC; Liu GY; Chuang TC; Lin YS; Wuu JA; Law SL
Oncogene; 1998 Jan; 16(4):547-54. PubMed ID: 9484845
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products.
Kokai Y; Dobashi K; Weiner DB; Myers JN; Nowell PC; Greene MI
Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889
[TBL] [Abstract][Full Text] [Related]
16. Biology and therapy with biologic agents in gynecologic cancer.
Wiener JR; Berchuck A; Bast RC
Curr Opin Oncol; 1992 Oct; 4(5):946-54. PubMed ID: 1457511
[TBL] [Abstract][Full Text] [Related]
17. Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer.
Xing X; Matin A; Yu D; Xia W; Sorgi F; Huang L; Hung MC
Cancer Gene Ther; 1996; 3(3):168-74. PubMed ID: 8725881
[TBL] [Abstract][Full Text] [Related]
18. Gene amplification in human lung cancer. The myc family genes and other proto-oncogenes and growth factor genes.
Bergh JC
Am Rev Respir Dis; 1990 Dec; 142(6 Pt 2):S20-6. PubMed ID: 2174659
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
Berchuck A; Kamel A; Whitaker R; Kerns B; Olt G; Kinney R; Soper JT; Dodge R; Clarke-Pearson DL; Marks P
Cancer Res; 1990 Jul; 50(13):4087-91. PubMed ID: 1972347
[TBL] [Abstract][Full Text] [Related]
20. The biology of ovarian cancer.
Boente MP; Hurteau J; Rodriguez GC; Bast RC; Berchuck A
Curr Opin Oncol; 1993 Sep; 5(5):900-7. PubMed ID: 8218503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
